Geron Running Again

 

Geron's (GERN) vital signs keep getting stronger.

The biotechnology company, which enjoyed a muscular rally following coverage by TheStreet.com earlier this week, extended its gains after reporting a new medical breakthrough on Thursday. In a preview of an article due out by Stem Cells in August, the company unveiled fresh progress on a stem cell-related treatment for diabetes.

Specifically, Geron said that it has differentiated embryonic stem cells into clusters that "secrete insulin in response to elevated glucose levels." The advance could offer hope for huge crowds of people who suffer from type 1 diabetes.

Geron shareholders sure feel optimistic. They saw the company's stock -- which was stuck around $7 just two months ago -- rocket 9.6% to $9.03 on the news.

Robert Lawton, managing partner of New York's Catoosa Fund, feels that Geron shareholders have finally started seeing the type of payoff that they deserve.

"If Geron had published a press release like this a month ago -- or even a week ago -- it wouldn't have budged the stock," says Lawton, whose firm has a long position in the company itself. "The stock could have even ended up red for the day.

"But it's on the radar screen now."

Lawton feels that Geron's latest run has been fueled by a "coalescence" of favorable events, starting with TheStreet.com's big story on Monday. He says that new investors -- including technical experts, momentum players and "lazy brokers looking for new ideas" -- seem to be piling into the stock quite heavily this week.

Geron's stock has broken through several technical averages, on extremely heavy volume, during the recent rally.

"There really hasn't been a lot of big institutional interest in the stock until this week," Lawton says. "But you've seen the market: It's looking for something to chase. [And] this is a very sexy story."

>To order reprints of this article, click here: Reprints

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,890.46 1,351.95 2,927.23 20.47
Oil *
118.75
UP
6.51
UP
1.99
UP
11.37
UP
0.72
10 Yr
2.05%
SPDR Gold
168.02
+0.05%
+0.15%
+0.39%
+3.65%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet